Breast Cancer Index (BCI)

Use predictive power to personalize her path

Who is really likely to benefit from extended endocrine therapy in ER+ early-stage breast cancer?

BCI can help you decide: extend or end endocrine therapy at year 5 and beyond1-3

Learn More

BCI is the only validated biomarker test that is:1-4

  • Predictive for the likelihood of benefit from extended endocrine therapy and
  • Prognostic for the risk of late-distant recurrence (Years 5 - 10) in N0 and N1 patients
  • Shown to change physician treatment recommendations related to extended endocrine therapy in 26% of patients
Learn More
# # # # # # # # # # # # # # # # # # # # # # # # Physician walking down a path with patient

The Prognostic and Predictive Power of Breast Cancer Index.

Different Genomic Tools for Clinical Use in Breast Cancer

  1. Sgroi DC, et al. J Natl Cancer Inst. 2013;105:1036-1042.
  2. Sgroi DC, et al. Lancet Oncol. 2013;14:1067-76.
  3. Zhang Y, et al. Clin Cancer Res. 2013;19:4196-4205.
  4. Sanft T, et al. Breast Cancer Res Treat. 2015;154(3):533-41.
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.